KRAS G12C inhibitors and methods of using the same
US-10532042-B2 · Jan 14, 2020 · US
Substituted piperazines as KRAS G12C inhibitors
US11285156B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11285156-B2 |
| Application number | US-201916438349-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 11, 2019 |
| Priority date | Jun 12, 2018 |
| Publication date | Mar 29, 2022 |
| Grant date | Mar 29, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are KRAS G12C inhibitors, such ascomposition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of:
Assignees
Inventors
- Allen John Gordon
- Lanman Brian Alan
- Chen Jian
- Reed Anthony B
- Cee Victor J
- Liu Longbin
- Lopez Patricia
- Wurz Ryan Paul
- Nguyen Thomas T
- Booker Shon
- Allen Jennifer Rebecca
- Chu-Moyer Margaret
- Amegadzie Albert
- Chen Ning
- Goodman Clifford
- Low Jonathan D
- Ma Vu Van
- Minatti Ana Elena
- Nishimura Nobuko
- Pickrell Alexander J
- Wang Hui-Ling
- Shin Youngsook
- Siegmund Aaron C
- Yang Kevin C
- Tamayo Nuria A
- Walton Mary
- Xue Qiufen
Classifications
having two nitrogen atoms, e.g. dilazep · CPC title
against tumor tissues, cells, antigens · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Antineoplastic agents · CPC title
Bridged systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11285156B2 cover?
- Provided herein are KRAS G12C inhibitors, such ascomposition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).